Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Am J Hosp Palliat Care ; 33(5): 456-62, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25550442

RESUMEN

To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS). The symptom severity was evaluated by the memorial delirium rating scale (MDAS) on days 0, 3, and 7 following intervention. Significant improvements in total MDAS scores were found in all groups on day 3. However, on day 7, only the short T1/2 group and MARTA group showed significant improvement. Consideration of an AP's pharmacological properties may be helpful for improving the outcomes of pharmacological delirium intervention in patients with cancer.


Asunto(s)
Antipsicóticos/farmacocinética , Antipsicóticos/uso terapéutico , Delirio/tratamiento farmacológico , Delirio/etiología , Neoplasias/complicaciones , Anciano , Anciano de 80 o más Años , Antipsicóticos/administración & dosificación , Benzodiazepinas/farmacocinética , Benzodiazepinas/uso terapéutico , Estudios Transversales , Femenino , Semivida , Haloperidol/farmacocinética , Haloperidol/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Olanzapina , Fumarato de Quetiapina/farmacocinética , Fumarato de Quetiapina/uso terapéutico , Risperidona/farmacocinética , Risperidona/uso terapéutico , Índice de Severidad de la Enfermedad
2.
Support Care Cancer ; 21(10): 2777-81, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23722950

RESUMEN

PURPOSE: The primary aim of this study was to clarify the effect of sublingual scopolamine on the intensity of nausea. PATIENTS AND METHODS: This was an open uncontrolled study, and the study participants were cancer patients consecutively admitted to a palliative care unit in Japan. When the patients had nausea, they were administered a solution of scopolamine at 0.15 mg sublingually. The intensities of nausea were assessed using the 6-point Numerical Rating Scale (NRS 0 = no nausea to 5 = worst nausea) before and 15, 30, and 60 min after administration. Primary endpoints were (1) changes in the NRS of nausea and (2) percentage of patients who achieved a decrease in NRS of 1 or more points 15 min after treatment. RESULTS: Twenty-six patients were recruited for this study. The median NRS significantly decreased from 3.0 (range, 1-5) to 1.5 (0-5) after 15 min, and 84 % (n = 21) of the patients achieved a decrease in NRS of 1 or more points after 15 min. In addition, the median NRS significantly decreased from 3.0 (before) to 0 (30 min) and 0 (60 min). The percentage of patients who achieved a decrease in NRS over 1 point was 96 % (n = 25) in 30 min and 100 % (n = 26) in 60 min. Fifteen percent (n = 4) showed drowsiness. No other adverse effects were reported. CONCLUSION: Sublingually administered scopolamine may be effective for managing nausea in terminally ill cancer patients. Randomized controlled trials are promising.


Asunto(s)
Antieméticos/administración & dosificación , Náusea/tratamiento farmacológico , Náusea/etiología , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológico , Cuidados Paliativos/métodos , Escopolamina/administración & dosificación , Administración Sublingual , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Enfermo Terminal
3.
J Anaesthesiol Clin Pharmacol ; 28(2): 194-9, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22557742

RESUMEN

BACKGROUND: Whether effect-site concentrations of propofol (Cep) at loss of consciousness and return of consciousness (LOC and ROC, respectively) in elderly women using Diprifusor are similar is unclear. We investigated whether differences in initial target Cep (Ctarget) alter similarities between Cep values at LOC and ROC. MATERIALS AND METHODS: In this study, female patients (n = 58, age = 72.5 ± 1.1 years) undergoing knee arthroplasty were administered propofol with Diprifusor. Cep at LOC and ROC were estimated for different Ctarget values (3.0-4.5 µg/ml). Pearson's correlation coefficient analysis and simple regression were performed to assess the relationship between Cep at LOC and ROC for each Ctarget. Differences in correlation coefficients of regression lines obtained from each Ctarget group were determined using the t-test. RESULTS: The different Ctarget groups did not show significant differences in total propofol levels and in Cep values at LOC or ROC. However, Cep at ROC was significantly higher than Cep at LOC when Ctarget was 4.0 and 4.5 µg/ml, whereas these Cep values were not significantly different in low Ctarget groups. Strong positive correlations were observed between Cep at LOC and ROC for all Ctarget groups. Regression coefficients for the different Ctarget groups were not significantly different. Compared to low (≤3.5 µg/ml) Ctarget groups, high Ctarget groups showed significantly shorter time until LOC. Induction quality was not significantly different among the groups. CONCLUSIONS: In elderly women, Cep values at LOC are strong predictors of Cep at ROC when Ctarget is 3.0-4.5 µg/ml. High Ctarget groups (≥4.0 µg/ml) exhibited shorter induction times with normal cardiovascular stability.

4.
J Palliat Med ; 13(12): 1495-8, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21155649

RESUMEN

The patient was a 57-year-old woman with malignant pleural mesothelioma. She had a past history of anxiety neurosis but not had any history of otological diseases. On admission to our hospice (day 1), she complained of dyspnea and wheezing associated with the progression of her underlying disease. After we started oral betamethasone (2 mg/d), dyspnea was alleviated and the frequency of wheezing was reduced. On day 3, she began to experience musical hallucinations that were manifested in opera/piano concert music and a child's voice. The episodes of musical hallucinations occurred approximately 10 times a day and disappeared spontaneously within several minutes. She had not experienced these symptoms before. We reduced the dose of betamethasone to 1 mg/d, but the musical hallucinations continued. Then on day 11, we switched betamethasone (1 mg/d) to prednisolone (10 mg/d) and we then gradually tapered off prednisolone. The frequency of musical hallucinations decreased and she ceased to experience musical hallucinations on day 29. However, on day 40, her dyspnea was aggravated again, so we started treatment with prednisolone (5 mg/d). Dyspnea was alleviated and no musical hallucinations occurred. On Day 51, dyspnea was worsened and we switched prednisolone to betamethasone (4 mg/d), which she hoped to use. The betamethasone alleviated the dyspnea but she developed musical hallucinations that were similar to the previous episodes. The musical hallucinations disappeared spontaneously 4-5 days later without changing the betamethasone. Musical hallucinations never occurred thereafter. She later died due to the exacerbation of disease.


Asunto(s)
Alucinaciones/inducido químicamente , Alucinaciones/prevención & control , Neoplasias Pleurales , Psicosis Inducidas por Sustancias/prevención & control , Esteroides/administración & dosificación , Esteroides/uso terapéutico , Cuidado Terminal , Betametasona/administración & dosificación , Betametasona/efectos adversos , Betametasona/uso terapéutico , Femenino , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Glucocorticoides/uso terapéutico , Alucinaciones/fisiopatología , Humanos , Mesotelioma , Persona de Mediana Edad , Prednisolona/administración & dosificación , Prednisolona/uso terapéutico , Psicosis Inducidas por Sustancias/etiología
5.
Masui ; 58(4): 480-3, 2009 Apr.
Artículo en Japonés | MEDLINE | ID: mdl-19364016

RESUMEN

Transfusion-related acute lung injury (TRALI) is a serious complication of transfusion of blood and blood components. TRALI is reported to be the most common cause of transfusion-associated death. TRALI has increasingly become known in the medical community. However, TRALI has been overlooked frequently because of poor knowledge of medical staffs. We report two cases of TRALI after massive transfusion due to massive bleeding during cardiovascular surgery. In the perioperative period, the diagnosis of TRALI is difficult to make because of coexistence of various factors leading to hypoxia. Thus, in this report, we discuss the management of these two cases focusing upon the differential diagnosis of TRALI.


Asunto(s)
Lesión Pulmonar Aguda/etiología , Atención Perioperativa/efectos adversos , Reacción a la Transfusión , Lesión Pulmonar Aguda/diagnóstico , Adulto , Anciano , Pérdida de Sangre Quirúrgica , Procedimientos Quirúrgicos Cardiovasculares , Resultado Fatal , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...